Clinical Trials

Please see the list below for clinical trials we are participating in. Please reach out to [email protected] for more information on the trials or if you have any questions about enrolling in research!

You can also check out the UCSF Clinical Trials website for more information on how clinical trials work and what you can expect if you decide to join a trial.


Active and Upcoming


Amyotrophic Lateral Sclerosis (ALS)

ASTRALS - Novartis Phase 2

Now Enrolling!

Full Study Name: A phase 2, randomized, double-blind, placebo-controlled parallel group study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) over 40 weeks followed by an Open-label Extension (ASTRALS)

Purpose: The purpose of the study is to find out whether the study treatment VHB937 is safe and slows disease progression in people with ALS who have had symptoms for no more than 2 years.

Participants: Adult participants with ALS. First signs of muscle weakness < 24 months, ALSFRS ≥ 30, SVC ≥ 60%

Study Length: Unless you decide to stop study treatment, you will be in the study as long as your Study Doctor feels that you are benefiting from your participation in the study or the study is cancelled. Before starting study treatment (screening period), you will visit the Study Doctor up to 3 times. Once you start the study treatment, you will visit the site about 11 times over the initial 40 weeks. During the study you will receive an intravenous infusion of study treatment every 4 weeks, while your safety and disease progression will be assessed every 12 weeks. If you decide to stop study treatment, you may continue visiting the site every 12 weeks until you decide to stop these visits. After that point, your Study Doctor will still continue checking on your health status via phone calls every 12 weeks to you, your relatives, or your personal doctor.

Sponsor: Novartis

Compensation: You will not be paid for being in this study; however, you will receive reasonable reimbursement for travel expenses as required for each study visit during your participation in this study.

Principal Investigator: Jill Goslinga, MD, MPH

I'm Interested

Multifocal Motor Neuropathy (MMN)

Empassion (ARGX-117-2302)

Now Enrolling!

Full Study Name: A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin in Adults With Multifocal Motor Neuropathy

Purpose: This study aims to evaluate the effect (efficacy) and safety of empasiprubart compared with intravenous immunoglobulin (IVIg) treatment in adults with multifocal motor neuropathy (MMN). This study will also check how empasiprubart affects the body, how it is absorbed and removed from the body, and how the immune system reacts to empasiprubart.

Participants: Adults subjects with MMN who are receiving IVIg at a treatment interval of once every 2, 3, 4, or 5 weeks. Eligible participants must have responded to IVIg in the past 5 years, with a clinically meaningful improvement. 

Eligibile participants may not receive cyclophosphamide, rituximab, ravulizumab, eculizumab, or mycophenolate mofetil within 6 months before the screening period.

Study Length: The study will last up to 78 weeks. The study includes a screening period, 2 study treatment periods (part A and part B), and a safety follow-up period.

The screening visit will take 1 full day and tests will be done to determine eligibility. The screening period will last up to 15 weeks. After the screening period, you will enter a 24-week study treatment period. You will be randomly assigned (like rolling dice) to 1 of 2 study treatment groups: empasiprubart and IVIg placebo OR placebo empasiprubart and IVIg. After completing part A, you will enter a 24-month study treatment period where you will recieve empasiprubart or placebo without IVIg. There will be a 15-month safety follow-up period after your final infusion. 

Sponsor: argenx BV

Compensation: You will not be paid for being in this study; however, you will receive reasonable reimbursement for travel expenses as required for each study visit during your participation in this study.

Principal Investigator: Madina Tugizova, MD

I'm Interested

Idiopathic Inflammatory Myopathy (IIM)

Myasthenia Gravis (MG)

RemeGen RC18G006

Now Enrolling!

Full Study Name: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study with an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis

Purpose: The purpose of this study is to evaluate the safety and effectiveness of an investigational drug called telitacicept (referred to as the “study drug”) for the treatment of generalized Myasthenia Gravis (“gMG”).  “Investigational” means this study drug has not been approved by regulatory such as the United States Food or Drug Administration (FDA) or health authorities for the treatment of gMG.

Participants: Adults subjects with gMG with positive antibodies against AChR or MuSK.

Study Length: You will be in the study for up to 84 weeks (a little over 1.5 years) if you complete the study.  The study is divided into 3 primary periods:

Screening: If you would like to be in this study, your study doctor will first check that you are qualified. This is called screening. Screening must be completed within 4 weeks before you start taking the study drug. The screening part of the study may be one or more visits to the study site.

Study Treatment:  There are 2 Study Treatment Periods

  • Primary Study Treatment Period:  This is the blinded part of the study and lasts 24 weeks.  Blinded means that no one will know if you are receiving placebo (inactive substance) or telitacicept during this period.
  • Open Label Study Treatment (OLE) Period:  If you are eligible and willing to enter the OLE Period as assessed by your study doctor, you will receive the study drug, telitacicept 240 mg for an additional 48 weeks. This study phase is called the “open label” period because both you and the study staff know you are receiving the telitacicept 240 mg dose.

Follow-up: Everyone that completes the study will be required to come to the study site for 2 safety follow-up visits so the study doctor and staff can monitor your health after you have stopped taking the study drug. 

Sponsor: argenx BV

Compensation: You will not be paid for being in this study; however, you will receive reasonable reimbursement for travel expenses as required for each study visit during your participation in this study.

Principal Investigator: Pritikanta Paul, MD

I'm Interested

Inclusion Body Myositis (IBM)

 


Completed/Closed